TP53 and myelodysplastic syndrome: Our findings corroborate the higher incidence of TP53 mutations among high-risk MDS, that molecular markers such as TP53 and SRSF2 mutations provide additional prognostic data to guide clinical decisions in high-risk MDS and that the use of mutation analysis during follow up may help to identify patients who are progressing before the onset of signs of progression.